Be Balanced Probiotic is a food supplement consisting of 2 sporogenic probiotics, Lactobacillus sporogenes and Bacillus subtilis, which contribute to the balance of the intestinal flora and to the maintenance of good bowel function.
Bacillus coagulans (or Lactobacillus sporogenes) and Bacillus subtilis are two spore-forming probiotic bacteria. According to FAO (Food and Agriculture Organization of the United Nations) and WHO (World Health Organization), probiotics are “live micro-organisms which when administered in adequate amounts confer a health benefit on the host”. Probiotics must be able to survive through the gastrointestinal tract (which means in an acidic environment and in the presence of bile salts and digestive enzymes), in order to reach and colonize the gut, and proliferate. Probiotic bacteria are safe for human consumption providing a variety of beneficial effects on the host, such as the regulation and maintenance of gut’s physiological microbiota and the balance of gut’s homeostasis, the inhibition of pathogens’ and other harmful micro-organisms’ colonization and growth, the stabilization of the gastrointestinal tract’s function, the stimulation of immune responses etc. They are administered either as a preventive measure or as a therapeutic agent. Nowadays, spore-forming probiotics, especially of the genus Bacillus, are widely used in humans as dietary supplements. They are more tolerant to the environmental conditions of the digestive tract and unlike other probiotic bacteria the entire administrated dose of bacilli reaches the small intestine tract without loss. Moreover, they have the ability to produce anti-microbial substances (bacteriocins), that suppress the growth of intestinal pathogens and other competitive micro-organisms, and contribute to the overall better functioning of the intestine even in cases of disorders such as the Irritable bowel syndrome (IBS). Bacillus coagulans and B. subtilis strains have been reported as “safe” by the European Union Food Safety Authority-EFSA (QPS system- Qualified Presumption of Safety) and the U.S. Food and Drug Administration-FDA (GRAS-Generally Recognized Αs Safe). Bacillus coagulans has been found to be effective against acute diarrhea and abdominal discomfort, but also effective in the management of the clinical symptoms and the depression of IBS patients. As for Bacillus subtilis, it contributes to the maintenance of the healthy gut microbiota and the stimulation of elderly peoples’ immune responses.
FAO (2001). Health and Nutrition Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria: report of a joint FAO/WHO expert consultation, Cordoba, Argentina, 1-4 October 2001.
Elisashvili, V., Kachlishvili, E., & Chikindas, M.L. (2019). Recent Advances in the Physiology of Spore Formation for Bacillus Probiotic Production. Probiotics and Antimicrobial Proteins, 11 (3): 731-747. https://doi.org/10.1007/s12602-018-9492-x
Catinean, A., Neag, A.M., Nita, A., Buzea, M., & Buzoianu, A.D. (2019). Bacillus spp. Spores-A Promising Treatment Option for Patients with Irritable Bowel Syndrome. Nutrients, 11 (9): 1968. https://doi.org/10.3390/nu11091968
Soman, R.J., & Swamy, M.V. (2019). A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend for undiagnosed gastrointestinal discomfort. International Journal of Colorectal Disease, 34 (11): 1971-1978. https://doi.org/10.1007/s00384-019-03416-w
Maity, C., & Gupta, A.K. (2019). A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. European Journal of Clinical Pharmacology, 75 (1): 21-31. doi: 10.1007/s00228-018-2562-x
Majeed, M., Nagabhushanam, K., Natarajan, S., Sivakumar, A., Ali, F., Pande, A., Majeed, S. & Karri, S.K. (2016). Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutrition Journal, 15: 21. https://doi.org/10.1186/s12937-016-0140-6
Majeed, M., Nagabhushanam, K., Arumugam, S., Majeed, S., Ali, F. (2018). Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food & Nutrition Research, 62: 1218. https://doi.org/10.29219/fnr.v62.1218
Hatanaka, M., Yamamoto, K., Suzuki, N., Iio, S., Takara, T., Morita, H., Takimoto, T., & Nakamura, T. (2018). Effect of Bacillus subtilis C-3102 on loose stools in healthy volunteers. Beneficial Microbes, 9 (3): 357-365. https://doi.org/10.3920/bm2017.0103
Lefevre, M., Racedo, S.M., Ripert, G., Housez, B., Cazaubiel, M., Maudet, C., Justen, P., Marteau, P., & Urdaci, M.C. (2015). Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study. Immunity & Ageing, 12: 24. https://doi.org/10.1186/s12979-015-0051-y
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.